(MY) Dimension in the stationary (laboratory) frame of reference in the plane orthogonal to the direction of the static magnetic field (B0 and H0), z, and orthogonal to x, the other dimension in this plane. This is commonly defined to be in the direction of the phase encoding gradient.

(LE) Myocardial late enhancement in contrast enhanced cardiac MRI has the ability to precisely delineate myocardial scar associated with coronary artery disease. Viability imaging implies evaluating infarcted myocardium to see whether there is enough viable tissue available for revascularization. The reversal of myocardial dysfunction is particularly relevant in patients with depressed ventricular function because revascularization improves long-term survival. In comparison to SPECT and PET imaging, myocardial late enhancement MRI demonstrates areas of delayed enhancement exactly in correlation with the infarcted region.
Viability on cardiac MRI (CMR) is based on the fact that all infarcts enhance vividly 10-15 minutes after the administration of intravenous paramagnetic contrast agents. This enhancement represents the accumulation of gadolinium in the extracellular space, due to the loss of membrane integrity in the infarcted tissue. This phenomenon of delayed hyperenhancement has been proven to correlate with the actual extent of the infarct.
MRI myocardial late enhancement can quantify the size, location and transmural extent of the infarct. If the transmural extent of the infarct (region of enhancement on MRI) is less than 50% of the wall thickness, there will be improved contractility in that segment following revascularization. In areas of hypokinesia, if there is a rim of "black" or non-infarcted myocardium that is not contracting well, it indicates the presence of hibernating myocardium, which is likely to improve after revascularization of the artery supplying that particular territory.
The total duration of a myocardial late enhancement MR imaging protocol for viability is approximately 30 minutes, including scout images, first-pass images, cine images in two planes, and delayed myocardial enhancement images. In order to assess viable myocardium, the gadolinium contrast agent is injected at a dose of 0.15 to 0.2 mmol/kg. After about 10 minutes, short axis and long axis views (see cardiac axes) of the heart are obtained using an inversion prepared ECG gated gradient echo sequence. The inversion pulse is adjusted to suppress normal myocardium. Areas of nonviable myocardium retain extremely high signal intensity, black areas show normal tissue.

For Ultrasound Imaging (USI) see Myocardial Contrast Echocardiography at Medical-Ultrasound-Imaging.com.

[This entry is marked for removal.]

Nihon Schering KK, was a subsidiary of Schering in Japan.
In June 2006 Bayer AG has bought the majority of shares of Schering AG. As a result of this take-over Schering AG has been renamed in December 2006 in Bayer Schering Pharma AG.

This function equalizes the signal intensity when surface coils are used. By using this filter, the signal intensity of the region close to the coil is reduced, and the signal intensity of the area remote to the coil is increased. Also called homogeneity correction.

(NMR) Nuclear Magnetic Resonance is a physical phenomenon of the magnetic property of nuclei, which have a positive nuclear spin quantum number.
Under the influence of an external static magnetic field this nuclei will precess about the direction of the magnetic field with an angular frequency (Larmor frequency). Through absorption and emission of RF energy (gradients, RF coils) at the resonance frequency (Larmor equation) and the processing of this raw data by the Fourier transformation - physical, chemical, electronic, and structural information about molecules can be obtained (NMR Magnetic Resonance Spectroscopy, Magnetic Resonance Imaging).